contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


invitation-to-the-presentation-of-bicos-interim-report-q1-2026

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

BICO Group operates in the biotechnology industry and focuses on the development and manufacturing of technologies for cell-based research and medical development. The company's products are aimed at researchers and pharmaceutical companies. The business is global with a main presence in Europe, North America and Asia. BICO Group was founded in 2016 and is headquartered in Gothenburg, Sweden.

Bico Group Audiocast Q3’25:                   Inderes              BICO, Audiocast, Q3'25 - Inderes    Time: 2025-11-04 10:00 Language: en Language: en Sector: Health care - Pharmaceuticals & Biotechnology Activity: Audiocast with teleconference

Mattek and Visikol sold for $80M at 4x sales price. I can’t be bothered to look up what was paid for these now, but it sounds good. This company’s journey from the COVID bubble to here has certainly been quite a mess. Acquired all sorts of things suitable for the CEO’s visions at exorbitant valuations (fortunately, partly using its own overpriced shares) - then hit a wall as interest rates rose, and now divesting the same acquisitions.

Let’s revive this thread again. Bico’s 2024 results are out, and after a couple of years in the wilderness, things actually look quite good. Losses have significantly decreased from 2023, and Q4/2024 has been a profitable quarter.   Source: https://bico.com/investors/ If anyone is still on board, the ride could get much better from here. This definitely beats Hesuli =)

This news published in early July hadn’t been posted here yet: Next step in Sartorius partnership finalized: several sub-sales and distribution agreements as well as R&D project agreements have been signed                   BICO              Single Press release    BICO enables and automates the life science lab of the future.         Est. reading time: 1 minute                               So, they signed agreements with Sartorius in May-June, and as a result, the share price has already risen by +30% since the beginning of June.

Dagens industri – 7 Jun 23              Kraschrisk i medicinteknikbolaget    Ensidigt fokus på tillväxt på bekostnad av den finansiella stabiliteten fick Viaplay- och SBB-aktierna på fall och tvingade bort bolagens vd:ar.                             Apparently there is some story about Bico here, but it is only visible to subscribers.

BICO              Single Press release    BICO enables and automates the life science lab of the future.         Est. reading time: 1 minute                               Financial statement published at 7:00. Interesting to see what the market thinks.

Holy shit. There’s a bloodbath coming at 10…

BICO Group

BICO’s Interim report 2026 will be published on Wednesday April 29, 2026, at 07:00am CEST. Following the release of the interim report, a telephone conference with the opportunity to ask questions...

<div class="mfn-preamble"><p><strong>BICO’s Interim report 2026 will be published on Wednesday April 29, 2026, at 07:00am CEST. Following the release of the interim report, a telephone conference with the opportunity to ask questions will be held in English at 10:00 am CEST on the same day, with President &amp; CEO Maria Forss and CFO Ewa Linsäter presenting the interim report.</strong></p></div><div class="mfn-body"><p>Information about the presentation and webcast<br>The presentation will be available on BICO’s website from 09:00am CEST. <br><a href="https://bico.com/investors/" rel="noopener">https://bico.com/investors/</a></p><p>If you wish to participate via webcast, please use the link below: <br><a href="https://urldefense.com/v3/__https://bico.events.inderes.com/q1-report-2026__;!!C05lT65P!2ZCadDoIYe_h6PuJBC7IXxO3WmFztp7g4Cd4luWdSx5ToKnincgAse53FgUO6OcY_A_r5DfKHdbQL7GI4QE$" rel="noopener">https://bico.events.inderes.com/q1-report-2026</a></p><p>If you wish to participate via teleconference, please register via the link below. After registration you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via teleconference.&nbsp;<br><a href="https://urldefense.com/v3/__https:/events.inderes.com/bico/q1-report-2026/dial-in__;!!C05lT65P!2ZCadDoIYe_h6PuJBC7IXxO3WmFztp7g4Cd4luWdSx5ToKnincgAse53FgUO6OcY_A_r5DfKHdbQNU1DDnM$" rel="noopener">https://events.inderes.com/bico/q1-report-2026/dial-in</a></p></div><div class="mfn-footer mfn-2c4f87b6577c"><p><strong class="mfn-heading-1">For further information, please contact:</strong><br>Ewa Linsäter, Chief Financial Officer, BICO Group AB<br>Phone: +46 766 33 32 33<br>E-mail: <a href="mailto:ewa.linsater@bico.com" rel="noopener">ewa.linsater@bico.com</a></p></div><div class="mfn-footer mfn-f3d84de701a0"><p><em>The information was submitted for publication, through the agency of the contact person set out above on April 15, 2026, at 07.00am CEST.</em></p></div><div class="mfn-footer mfn-31d379c491ca"><p><strong class="mfn-heading-1">About BICO</strong><br><a href="https://bico.com/" rel="noopener">BICO</a> is a lab automation partner and provider of selected workflows to pharma and biotech. With 53,600+ instruments installed in over 65 countries, BICO products, software, and solutions are found in more than 3,500 laboratories, including the world’s top 20 pharmaceutical companies, and have been cited in over 12,900 publications. BICO strives towards the vision to enable and automate the life science lab of the future. BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. <a href="http://www.bico.com" rel="noopener">www.bico.com</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a class="mfn-generated mfn-primary" href="https://storage.mfn.se/bd311b88-ac2f-4d24-91c0-18f41a7a61f1/invitation-to-the-presentation-of-bicos-interim-report-q1-2026.pdf" rel="noopener">Invitation to the presentation of BICO’s Interim report Q1 2026</a></p></div>